News Releases

News Releases

Jun 03, 2024

Merus’ MCLA-129 Demonstrates Promising Single-Agent Efficiency in METex14 NSCLC in Poster Presentation at the 2024 ASCO® Annual Meeting

UTRECHT, The Netherlands and CAMBRIDGE, Mass. , June 03, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), today announced the
Jun 02, 2024

Merus Presents Interim Data on MCLA-145 Monotherapy and in Combination with Pembrolizumab at the 2024 ASCO® Annual Meeting

UTRECHT, The Netherlands and CAMBRIDGE, Mass. , June 02, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), today announced updated
May 29, 2024

Merus Announces Pricing of Upsized Public Offering of Common Shares

UTRECHT, The Netherlands and CAMBRIDGE, Mass. , May 29, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), today announced the
May 29, 2024

Merus to Participate in a Fireside Chat at the Jefferies Global Healthcare Conference

UTRECHT, The Netherlands and CAMBRIDGE, Mass. , May 29, 2024 (GLOBE NEWSWIRE) -- Merus N.V . (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), today announced that Bill Lundberg , M.D., President, Chief
May 28, 2024

Merus N.V. Announces Proposed Public Offering of Common Shares

UTRECHT, The Netherlands and CAMBRIDGE, Mass. , May 28, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), today announced the
May 28, 2024

Merus’ Petosemtamab in Combination with Pembrolizumab Interim Data Demonstrates Robust Response Rate and Favorable Safety Profile in 1L r/m HNSCC

67% response rate observed among 24 evaluable patients Conference Call on Tuesday, May 28 th at 8 a.m. ET UTRECHT, The Netherlands and CAMBRIDGE, Mass. , May 28, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing
May 23, 2024

Merus Announces Publication of Abstracts for Presentation at the 2024 ASCO® Annual Meeting

MCLA-145 monotherapy and in combination with pembrolizumab rapid oral session presentation: June 2, 2024 , 11:30 a.m.-1:00 p.m. CT MCLA-129 in NSCLC with c-MET exon 14 skipping mutations poster presentation : June 3, 2024 , 1:30-4:30 p.m. CT UTRECHT, The Netherlands and CAMBRIDGE, Mass.
May 23, 2024

Merus Announces Publication of an Abstract on Petosemtamab with Pembrolizumab as 1L treatment of r/m HNSCC at the 2024 ASCO® Annual Meeting

-   60% response rate observed among 10 evaluable patients -   F avorable safety profile in 26 patients enrolled as of the abstract cutoff date , with no significant overlapping toxicities observed -   Conference call on Tuesday, May 28 at 8:00 a.m. ET to discuss full ASCO ® data set UTRECHT, The
May 13, 2024

Petosemtamab granted Breakthrough Therapy Designation by the U.S. FDA

Petosemtamab granted BTD for the treatment of previously treated HNSCC UTRECHT, The Netherlands and CAMBRIDGE, Mass. , May 13, 2024 (GLOBE NEWSWIRE) -- Merus N.V . (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and
May 08, 2024

Merus Announces Financial Results for the First Quarter 2024 and Provides Business Update

Petosemtamab in combination with pembrolizumab in 1L HNSCC initial interim clinical data at 2024 ASCO Annual Meeting; preparing for a potential phase 3 trial Zeno BLA accepted for priority review by the FDA for the treatment of NRG1+ NSCLC and PDAC Based on the Company’s current operating plan,
May 06, 2024

Merus Announces U.S. FDA Acceptance and Priority Review of Biologics License Application for Zeno for the Treatment of NRG1+ NSCLC and PDAC

If approved, Zeno will be the first targeted therapy for NRG1+ cancer UTRECHT, The Netherlands and CAMBRIDGE, Mass. , May 06, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific
Apr 24, 2024

Merus Announces Abstracts Accepted for Presentation at the 2024 ASCO Annual Meeting

Petosemtamab in combination with pembrolizumab in 1L HNSCC initial interim clinical data selected for rapid oral session presentation MCLA-145 as monotherapy or in combination with pembrolizumab in solid tumors initial interim clinical data selected for rapid oral session presentation MCLA-129 in
Apr 08, 2024

Merus Presents Preclinical Data Demonstrating Efficacy of Zeno in Cancer Models with High NRG1 Expression at the AACR Annual Meeting 2024

UTRECHT, The Netherlands and CAMBRIDGE, Mass. , April 08, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “the Company”, “we”, or “our”), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), today announced
Apr 03, 2024

Merus to Participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference

UTRECHT, The Netherlands and CAMBRIDGE, Mass. , April 03, 2024 (GLOBE NEWSWIRE) -- Merus N.V . (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), today announced that Bill Lundberg , M.D., President, Chief
Mar 06, 2024

Gilead and Merus Announce Collaboration to Discover Novel Antibody-Based Trispecific T-Cell Engagers

– Gilead Receives Exclusive Option to License Novel Trispecific Therapeutics  Resulting from the Collaboration – Foster City, Calif., [March 6, 2024] – Gilead Sciences, Inc. (Nasdaq:GILD) and Merus N.V. (Nasdaq:MRUS) today announced a research collaboration, option and license agreement to discover
Mar 05, 2024

Merus Announces Publication of an Abstract for Presentation at the AACR Annual Meeting 2024: Zeno is effective in cancer models with high NRG1 expression

Poster presentation: Monday, April 8, 2024, 9:00 am-12:30 p.m. PT UTRECHT, The Netherlands and CAMBRIDGE, Mass. , March 05, 2024 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific
Mar 04, 2024

Merus to Participate in a Fireside Chat at the Leerink Partners Global Biopharma Conference

UTRECHT, The Netherlands and CAMBRIDGE, Mass. , March 04, 2024 (GLOBE NEWSWIRE) -- Merus N.V . (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), today announced that Bill Lundberg , M.D., President, Chief
Feb 28, 2024

Merus Announces Financial Results for the Fourth Quarter and Full Year 2023 and Provides Business Update

-   Petosemtamab in 1L HNSCC in combination with pembrolizumab initial interim clinical data planned for 2Q24; preparing for a potential phase 3 trial -   Petosemtamab in 2L+ HNSCC phase 3 trial planned to initiate mid-2024; interim clinical data planned for 2H24 -   Petosemtamab in 2L CRC: cohort
Jan 31, 2024

Merus to Participate in Upcoming Investor Conferences

UTRECHT, The Netherlands and CAMBRIDGE, Mass. , Jan. 31, 2024 (GLOBE NEWSWIRE) -- Merus N.V . (Nasdaq: MRUS), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics ® and Triclonics ® ), today announced that Bill Lundberg , M.D., President, Chief